Active substance
Omeprazole
- SFDA 41
- US FDA 36
- Health Canada 11
- US price lines 14
- NHS prices 12
- WHO EML 1
- Safety 18
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ACILOC | 40 mg | Gastro-resistant capsule, hard · Oral use | 28 Blister | SAR 120.30 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| ACILOC | 40 mg | Gastro-resistant capsule, hard · Oral use | 7 Blister | SAR 30.50 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| ACILOC | 40 mg | Gastro-resistant capsule, hard · Oral use | 14 Blister | SAR 61.00 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| ACILOC | 20 mg | Gastro-resistant capsule, hard · Oral use | 28 Blister | SAR 88.90 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| ACILOC | 20 mg | Gastro-resistant capsule, hard · Oral use | 14 Blister | SAR 45.95 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| ACILOC | 20 mg | Gastro-resistant capsule, hard · Oral use | 7 Blister | SAR 22.95 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| Bloka | 40 | Powder and solvent for solution for infusion · Intravenous use | 1 Vial | SAR 22.40 | Generic · Prescription | Advanced Pharmaceutical Industries | Valid |
| EMILOK 20MG CAPSULES | 20 mg | Capsule · Oral use | 14 Bottle | SAR 37.20 | Generic · Prescription | GLOBAL PHARMA | Valid |
| EPIRAZOLE 20MG CAPS(E.C.PELLETS) | 20 mg | Capsule · Oral use | 14 Blister | SAR 23.35 | Generic · Prescription | EIPICO | Valid |
| Emilok | 40 mg | Gastro-resistant capsule, hard · Oral use | 14 Bottle | SAR 45.10 | Generic · Prescription | GLOBAL PHARMA CO LLC | Valid |
| Emopack | 40 mg | Powder for solution for injection/infusion · Intravenous use | 1 Vial | SAR 22.50 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Emopack | 40 mg | Powder for solution for injection/infusion · Intravenous use | 10 Vial | SAR 225.00 | Generic · Prescription | SPIMACO | Valid |
| GASEC 20MG GASTRO CAPS | 20 mg | Gastro-resistant capsule, hard · Oral use | 28 Blister | SAR 48.40 | Generic · Prescription | ALPHA PHARMA INDUSTRY | Valid |
| GASEC 20MG GASTRO CAPS | 20 mg | Gastro-resistant capsule, hard · Oral use | 14 Blister | SAR 27.50 | Generic · Prescription | ALPHA PHARMA INDUSTRY | Valid |
| GASEC 40MG GASTRO CAPSULES | 40 mg | Gastro-resistant capsule, hard · Oral use | 28 Blister | SAR 79.35 | Generic · Prescription | ALPHA PHARMA INDUSTRY | Valid |
| GASEC 40MG GASTRO CAPSULES | 40 mg | Gastro-resistant capsule, hard · Oral use | 14 Blister | SAR 45.10 | Generic · Prescription | ALPHA PHARMA INDUSTRY | Valid |
| HYPOSEC 20 MG CAPSULE | 20 mg | Capsule · Oral use | 14 Blister | SAR 31.60 | Generic · Prescription | Ram Pharmaceutical Industries | Valid |
| LOSEC MUPS 10 MG TAB | 10 mg | Gastro-resistant tablet · Oral use | 14 Blister | SAR 23.00 | NCE · Prescription | CHEPLAPHARM Arzneimittel GmbH | Valid |
| LOSEC MUPS 20MG TAB | 20 mg | Gastro-resistant tablet · Oral use | 14 Blister | SAR 45.95 | NCE · Prescription | CHEPLAPHARM Arzneimittel GmbH | Valid |
| OMECURE 40 MG POWDER FOR I.V. INJECTION | 40 mg | powder for solution for injection · Intravenous use | 10 Vial | SAR 270.90 | Generic · Prescription | LES LABORATOIRES MEDIS | Valid |
| OMEPREX 20 mg capsule | 20 mg | Capsule · Oral use | 14 Blister | SAR 45.95 | Generic · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| OMEPREX 20 mg capsule | 20 mg | Capsule · Oral use | 28 Blister | SAR 91.90 | Generic · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| OMERAL 10 mg capsule | 10 mg | Capsule · Oral use | 14 Blister | SAR 22.95 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| OMERAL 20 mg capsule | 20 mg | Capsule · Oral use | 14 Blister | SAR 45.95 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| OMISEC | 40 mg | Powder for solution for infusion · Intravenous use | 1 Vial | SAR 22.50 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
16 more — full table
Indications — CHI Daman Drug Formulary
ANESTHESIA-SUPPORTIVE AGENTS/ ASPIRATION PNEUMONIA PROPHYLAXIS; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT- H-PYLORI ERADICATION-EVIDENCE BASED FIRST LINE TREATMENT STRATEGY; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT- H-PYLORI ERADICATION-SALVAGE THERAPIES; BARIATRIC SURGERY; CORONARY ARTERY DISEASE; DENTAL ABSCESS-DENTAL PAIN; DYSPEPSIA; ENTEROPATHIC ARTHROPATHIES, UNSPECIFIED SITE REACTIVE ARTHROPATHY, UNSPECIFIED; GASTROESOPHAGEAL REFLUX DISEASE (GERD); LOW BACK PAIN; MARGINAL ZONE LYMPHOMA; MIGRAINE/ HEADACHE; MYASTHENIA GRAVIS; NON-ST WAVE ELEVATED MYOCARDIAL INFARCTION (NSTEMI); PAIN MANAGEMENT IN CANCER PATIENTS; PEPTIC ULCER; POSTOPERATIVE PAIN; PSORIATIC ARTHRITIS; RHEUMATOID ARITHRITIS-SUPPORTIVE CARE AND ADRS MANAGEMENT; ST-WAVE ELEVATED MYOCARDIAL INFARCTION (STEMI); THROMBOTIC THROMBOCYTOPENIC PURPURA; TUBERCULOSIS-SUPPORTIVE CARE
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| OMEPRAZOLE | 10MG; 20MG; 40MG | capsule, delayed rel pellets · oral | LANNETT CO INC | Prescription | 1 Nov 2002 |
| OMEPRAZOLE | 10MG; 20MG | capsule, delayed rel pellets · oral | SANDOZ | Prescription | 28 Jan 2003 |
| PRILOSEC OTC | EQ 20MG BASE | tablet, delayed release · oral | ASTRAZENECA | Over-the-counter | 20 Jun 2003 |
| OMEPRAZOLE | 40MG; 20MG; 10MG | capsule, delayed rel pellets · oral | DR REDDYS LABS LTD | Prescription | 22 Oct 2007 |
| OMEPRAZOLE | 10MG; 20MG; 40MG | capsule, delayed rel pellets · oral | IMPAX LABS | Prescription | 22 Oct 2007 |
| OMEPRAZOLE | 10MG; 20MG; 40MG | capsule, delayed rel pellets · oral | APOTEX | Prescription | 22 Oct 2007 |
| OMEPRAZOLE | 20MG | tablet, delayed release · oral | DEXCEL PHARMA | Over-the-counter | 4 Dec 2007 |
| PRILOSEC | EQ 2.5MG BASE/PACKET; EQ 10MG BASE/PACKET | for suspension, delayed release · oral | AZURITY | Prescription | 20 Mar 2008 |
| OMEPRAZOLE | 10MG; 20MG; 40MG | capsule, delayed rel pellets · oral | ACTAVIS LABS FL INC | Prescription | 30 May 2008 |
| OMEPRAZOLE | 40MG | capsule, delayed rel pellets · oral | SANDOZ | Prescription | 21 Jan 2009 |
| OMEPRAZOLE | 40MG; 10MG; 20MG | capsule, delayed rel pellets · oral | DR REDDYS LABS LTD | Prescription | 17 Apr 2009 |
| OMEPRAZOLE MAGNESIUM | EQ 20MG BASE | capsule, delayed release · oral | DR REDDYS LABS LTD | Over-the-counter | 5 Jun 2009 |
| OMEPRAZOLE | 10MG; 20MG; 40MG | capsule, delayed rel pellets · oral | ZYDUS PHARMS USA INC | Prescription | 19 Nov 2012 |
| OMEPRAZOLE | 10MG; 20MG; 40MG | capsule, delayed rel pellets · oral | GLENMARK PHARMS LTD | Prescription | 31 Oct 2014 |
| OMEPRAZOLE | 10MG; 20MG; 40MG | capsule, delayed rel pellets · oral | AUROBINDO PHARMA | Prescription | 19 Aug 2015 |
| OMEPRAZOLE | 20MG | capsule, delayed rel pellets · oral | TEVA PHARMS USA | Prescription | 13 Jun 2017 |
| OMEPRAZOLE | 10MG; 20MG; 40MG | capsule, delayed rel pellets · oral | BRECKENRIDGE | Prescription | 3 Jul 2017 |
| OMEPRAZOLE | 20MG | tablet, orally disintegrating, delayed release · oral | DEXCEL | Over-the-counter | 5 Jul 2017 |
| OMEPRAZOLE MAGNESIUM | EQ 20MG BASE | tablet, delayed release · oral | AUROBINDO PHARMA | Over-the-counter | 6 Jun 2018 |
| OMEPRAZOLE | 20MG | tablet, delayed release · oral | SUN PHARM | Over-the-counter | 12 Oct 2018 |
| OMEPRAZOLE | 20MG | tablet, delayed release · oral | DR REDDYS | Over-the-counter | 5 Nov 2018 |
| OMEPRAZOLE | 10MG; 20MG | capsule, delayed rel pellets · oral | HETERO LABS LTD III | Prescription | 26 Sep 2019 |
| OMEPRAZOLE MAGNESIUM | EQ 20MG BASE | tablet, delayed release · oral | HETERO LABS LTD III | Over-the-counter | 25 Mar 2020 |
| OMEPRAZOLE MAGNESIUM | EQ 20MG BASE | tablet, delayed release · oral | P AND L | Over-the-counter | 1 Jun 2020 |
| OMEPRAZOLE | 10MG; 20MG; 40MG | capsule, delayed rel pellets · oral | XIROMED | Prescription | 10 Dec 2020 |
11 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-OMEPRAZOLE | 02245058 | 20 MG | CAPSULE (DELAYED-RELEASE) · ORAL | APOTEX INC |
| BIO-OMEPRAZOLE | 02449927 | 20 MG | TABLET (DELAYED-RELEASE) · ORAL | BIOMED PHARMA |
| HEARTBURN CONTROL | 02435683 | 20 MG | CAPSULE (DELAYED-RELEASE) · ORAL | APOTEX INC |
| JAMP-OMEPRAZOLE DR | 02420198 | 20 MG | TABLET (DELAYED-RELEASE) · ORAL | JAMP PHARMA CORPORATION |
| LOSEC | 00846503 | 20 MG | CAPSULE (DELAYED-RELEASE) · ORAL | CHEPLAPHARM ARZNEIMITTEL GMBH |
| LOSEC MUPS | 02242462 | 20 MG | TABLET (DELAYED-RELEASE) · ORAL | CHEPLAPHARM ARZNEIMITTEL GMBH |
| OMEPRAZOLE | 02339927 | 20 MG | CAPSULE (DELAYED-RELEASE) · ORAL | PRO DOC LIMITEE |
| OMEPRAZOLE | 02348691 | 20 MG | CAPSULE (DELAYED-RELEASE) · ORAL | SANIS HEALTH INC |
| OMEPRAZOLE-20 | 02411857 | 20 MG | CAPSULE (DELAYED-RELEASE) · ORAL | SIVEM PHARMACEUTICALS ULC |
| TEVA-OMEPRAZOLE | 02295407 | 10 MG | TABLET (DELAYED-RELEASE) · ORAL | TEVA CANADA LIMITED |
| TEVA-OMEPRAZOLE | 02295415 | 20 MG | TABLET (DELAYED-RELEASE) · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | FT OMEPRAZOLE DR 20 MG TABLET | $0.3832 | per EA | 23 Sep 2026 |
| US NADAC | GNP OMEPRAZOLE DR 20 MG TABLET | $0.3832 | per EA | 23 Sep 2026 |
| US NADAC | GS OMEPRAZOLE DR 20 MG ODT | $0.4682 | per EA | 23 Sep 2026 |
| US NADAC | GS OMEPRAZOLE DR 20 MG TABLET | $0.3832 | per EA | 23 Sep 2026 |
| US NADAC | OMEPRAZOLE DR 10 MG CAPSULE | $0.07662 | per EA | 23 Sep 2026 |
| US NADAC | OMEPRAZOLE DR 20 MG CAPSULE | $0.02945 | per EA | 23 Sep 2026 |
| US NADAC | OMEPRAZOLE DR 20 MG ODT | $0.4682 | per EA | 23 Sep 2026 |
| US NADAC | OMEPRAZOLE DR 20 MG TABLET | $0.3832 | per EA | 23 Sep 2026 |
| US NADAC | OMEPRAZOLE DR 40 MG CAPSULE | $0.04982 | per EA | 23 Sep 2026 |
| US NADAC | OMEPRAZOLE MAG DR 20 MG CAP | $0.39509 | per EA | 23 Sep 2026 |
| US NADAC | OMEPRAZOLE MAG DR 20 MG TABLET | $0.47306 | per EA | 23 Sep 2026 |
| US NADAC | OMEPRAZOLE MAG DR 20.6 MG CAP | $0.39509 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Omeprazole 10mg dispersible gastro-resistant tablets | £11.41 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Omeprazole 10mg gastro-resistant capsules | £0.86 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Omeprazole 10mg gastro-resistant tablets | £10.02 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Omeprazole 10mg/5ml oral suspension sugar free | £136.79 | 75 ml | 1 Oct 2026 |
| NHS Drug Tariff | Omeprazole 1mg/ml oral suspension sugar free | £122.45 | 75 ml | 1 Oct 2026 |
| NHS Drug Tariff | Omeprazole 20mg dispersible gastro-resistant tablets | £16.76 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Omeprazole 20mg gastro-resistant capsules | £0.83 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Omeprazole 20mg gastro-resistant tablets | £6.62 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Omeprazole 20mg/5ml oral suspension sugar free | £258.13 | 75 ml | 1 Oct 2026 |
| NHS Drug Tariff | Omeprazole 40mg dispersible gastro-resistant tablets | £8.60 | 7 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Omeprazole 40mg gastro-resistant capsules | £0.67 | 7 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Omeprazole 40mg gastro-resistant tablets | £10.39 | 7 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 17.1. Antiulcer medicines · core
Gastrointestinal bleeding; Peptic ulcer, site unspecified; Gastro-oesophageal reflux disease
Parenteral > General injections > IV: 40 mg in vial (EML) | Oral > Liquid: 1 mg per mL powder for oral liquid; 4 mg per mL powder for oral liquid | Oral > Solid > dosage form: 10 mg; 20 mg; 40 mg
Safety signals and safety-related labeling changes
- US FDA 21 Nov 2024 YOSPRALA — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 1 May 2024 OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 1 May 2024 TALICIA — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Jul 2023 PRILOSEC — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Jul 2023 ZEGERID — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Jul 2023 ZEGERID — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 23 Nov 2022 ZEGERID OTC — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 1 Nov 2022 ZEGERID OTC — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 21 Oct 2022 OMEPRAZOLE — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 4 Oct 2022 PRILOSEC OTC — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 30 Sep 2022 OMEPRAZOLE — safety-related labeling change
Labeling sections changed: Warnings and Precautions - EMA PRAC 12 Jan 2017 PRAC signal: Incident chronic kidney disease (CKD) and progression to end stage renal disease (ESRD)
Action for MAH: update of the product information: No - US FDA 19 Dec 2016 PRILOSEC — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 1 Dec 2016 PRAC signal: Gastric polyps
Action for MAH: update of the product information: Yes - EMA PRAC 2 Sep 2016 PRAC signal: Incident chronic kidney disease (CKD) and progression to end stage renal disease (ESRD)
Action for MAH: update of the product information: No
Combinations containing Omeprazole
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.